Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Gabriele Luppi, Jean–Pierre Bronowicki et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 61
591 A prospective, multicenter, observational study on compliance to hepatitis C treatments (CHEOBS): Characteristics of HCV-infected patients with psychiatric disordersJean-Marie Lang, P. Cacoub, Denis Ouzan et al.|Journal of Hepatology|2006Cited by 1